New Global Expansion Report Benchmarks the Hidden Costs and Risks of Scaling Across 19 Markets 
cside Launches AI Agent Detection Toolkit, Enabling Websites to Block Agentic Attackers and Guide Agentic Shoppers 
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013 
Banle Group Hosts Inaugural ESG Forum with Industry Leaders, Pioneering Green Shipping Solutions Amid Global Decarbonization Push Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently…
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over…
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with…
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice…
Yield10 Bioscience to Present at the Benzinga Biotech Small Cap Conference on March 25, 2021
WOBURN, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural…
Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology…
ORYZON to Participate in Upcoming Virtual International Conferences in March and April
BIO-Europe Spring 2021 Kempen Life Sciences Conference 4th SACHS Annual Neuroscience Innovation Forum 2021 MADRID,…
Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
Company to host an investor conference call and webcast at 4:30pm ET on that day…
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) — APIE Therapeutics, a preclinical biopharma company pioneering…
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world…
Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical…
Foghorn Therapeutics Provides Corporate Update
– FHD-286 Phase 1 data anticipated as early as year-end 2021 – FHD-609 IND submission…
Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology…
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit…
Talis Appoints Jeryl Hilleman to Board of Directors
MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone…
ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021
Conference Call Scheduled for March 25, 2021 at 4:30 p.m. ET RAMSEY, N.J. and BOCA…
Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st
DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company…